 |
|||||
|
|||||
|
|||||
|
|||||
|
|||||
Previous Article | Next Article
The Journal of Neuroscience, May 1, 2002, 22(9):3708-3719
Prefrontal Dopamine D1 Receptors and Working Memory in Schizophrenia
Anissa Abi-Dargham1, 2, Osama Mawlawi1, 2, Ilise Lombardo1, Roberto Gil1, Diana Martinez1, Yiyun Huang1, Dah-Ren Hwang1, 2, John Keilp1, Lisa Kochan1, Ronald Van Heertum2, Jack M. Gorman1, 2, and Marc Laruelle1, 2 Departments of 1 Psychiatry and 2 Radiology, Columbia University College of Physicians and Surgeons and New York State Psychiatric Institute, New York, New York 10032
Studies in nonhuman primates documented that appropriate stimulation of dopamine (DA) D1 receptors in the dorsolateral prefrontal cortex (DLPFC) is critical for working memory processing. The defective ability of patients with schizophrenia at working memory tasks is a core feature of this illness. It has been postulated that this impairment relates to a deficiency in mesocortical DA function. In this study, D1 receptor availability was measured with positron emission tomography and the selective D1 receptor antagonist [11C]NNC 112 in 16 patients with schizophrenia (seven drug-naive and nine drug-free patients) and 16 matched healthy controls. [11C]NNC 112 binding potential (BP) was significantly elevated in the DLPFC of patients with schizophrenia (1.63 ± 0.39 ml/gm) compared with control subjects (1.27 ± 0.44 ml/gm; p = 0.02). In patients with schizophrenia, increased DLPFC [11C]NNC 112 BP was a strong predictor of poor performance at the n-back task, a test of working memory. These findings confirm that alteration of DLPFC D1 receptor transmission is involved in working memory deficits presented by patients with schizophrenia. Increased D1 receptor availability observed in patients with schizophrenia might represent a compensatory (but ineffective) upregulation secondary to sustained deficiency in mesocortical DA function.
Key words: dopamine; D1 receptors; schizophrenia; prefrontal cortex; working memory; positron emission tomography
Copyright © 2002 Society for Neuroscience 0270-6474/02/2293708-12$05.00/0
This article has been cited by other articles:
D. P. Prata, A. Mechelli, M. M. Picchioni, C. H. Y. Fu, T. Toulopoulou, E. Bramon, M. Walshe, R. M. Murray, D. A. Collier, and P. McGuire
Altered Effect of Dopamine Transporter 3'UTR VNTR Genotype on Prefrontal and Striatal Function in Schizophrenia
Arch Gen Psychiatry, November 1, 2009; 66(11): 1162 - 1172.
[Abstract] [Full Text] [PDF]
D. P. Prata, A. Mechelli, C. H. Y. Fu, M. Picchioni, T. Toulopoulou, E. Bramon, M. Walshe, R. M. Murray, D. A. Collier, and P. McGuire
Epistasis between the DAT 3' UTR VNTR and the COMT Val158Met SNP on cortical function in healthy subjects and patients with schizophrenia
PNAS, August 11, 2009; 106(32): 13600 - 13605.
[Abstract] [Full Text] [PDF]
O. D. Howes and S. Kapur
The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
Schizophr Bull, May 1, 2009; 35(3): 549 - 562.
[Abstract] [Full Text] [PDF]
P. M. Greenwood, M.-K. Lin, R. Sundararajan, K. J. Fryxell, and R. Parasuraman
Synergistic effects of genetic variation in nicotinic and muscarinic receptors on visual attention but not working memory
PNAS, March 3, 2009; 106(9): 3633 - 3638.
[Abstract] [Full Text] [PDF]
F. McNab, A. Varrone, L. Farde, A. Jucaite, P. Bystritsky, H. Forssberg, and T. Klingberg
Changes in Cortical Dopamine D1 Receptor Binding Associated with Cognitive Training
Science, February 6, 2009; 323(5915): 800 - 802.
[Abstract] [Full Text] [PDF]
A. Bertolino, L. Fazio, G. Caforio, G. Blasi, A. Rampino, R. Romano, A. Di Giorgio, P. Taurisano, A. Papp, J. Pinsonneault, et al.
Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia
Brain, February 1, 2009; 132(2): 417 - 425.
[Abstract] [Full Text] [PDF]
H. Takahashi, M. Kato, H. Takano, R. Arakawa, M. Okumura, T. Otsuka, F. Kodaka, M. Hayashi, Y. Okubo, H. Ito, et al.
Differential Contributions of Prefrontal and Hippocampal Dopamine D1 and D2 Receptors in Human Cognitive Functions
J. Neurosci., November 12, 2008; 28(46): 12032 - 12038.
[Abstract] [Full Text] [PDF]
M.-E. Bach, E. H. Simpson, L. Kahn, J. J. Marshall, E. R. Kandel, and C. Kellendonk
Transient and selective overexpression of D2 receptors in the striatum causes persistent deficits in conditional associative learning
PNAS, October 14, 2008; 105(41): 16027 - 16032.
[Abstract] [Full Text] [PDF]
J. A. Lieberman, F. P. Bymaster, H. Y. Meltzer, A. Y. Deutch, G. E. Duncan, C. E. Marx, J. R. Aprille, D. S. Dwyer, X.-M. Li, S. P. Mahadik, et al.
Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection
Pharmacol. Rev., September 1, 2008; 60(3): 358 - 403.
[Abstract] [Full Text] [PDF]
O. D. HOWES, A. J. MONTGOMERY, M. ASSELIN, R. M. MURRAY, P. M. GRASBY, and P. K. McGUIRE
Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis
The British Journal of Psychiatry, December 1, 2007; 191(51): s13 - s18.
[Abstract] [Full Text] [PDF]
R. Hwang, T. Shinkai, V. De Luca, Xingqun Ni, S. G. Potkin, J. A. Lieberman, H. Y. MeLtzer, and J. L. Kennedy
Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response
J Psychopharmacol, September 1, 2007; 21(7): 718 - 727.
[Abstract] [PDF]
J. A. Gray and B. L. Roth
Molecular Targets for Treating Cognitive Dysfunction in Schizophrenia
Schizophr Bull, September 1, 2007; 33(5): 1100 - 1119.
[Abstract] [Full Text] [PDF]
R. W. Buchanan, R. Freedman, D. C. Javitt, A. Abi-Dargham, and J. A. Lieberman
Recent Advances in the Development of Novel Pharmacological Agents for the Treatment of Cognitive Impairments in Schizophrenia
Schizophr Bull, September 1, 2007; 33(5): 1120 - 1130.
[Abstract] [Full Text] [PDF]
P. K. Dash, A. N. Moore, N. Kobori, and J. D. Runyan
Molecular activity underlying working memory
Learn. Mem., August 9, 2007; 14(8): 554 - 563.
[Abstract] [Full Text] [PDF]
J. L. Reilly, M. S. H. Harris, M. S. Keshavan, and J. A. Sweeney
Adverse effects of risperidone on spatial working memory in first-episode schizophrenia.
Arch Gen Psychiatry, November 1, 2006; 63(11): 1189 - 1197.
[Abstract] [Full Text] [PDF]
S. L. Pallas, P. Wenner, C. Gonzalez-Islas, M. Fagiolini, K. A. Razak, G. Kim, D. Sanes, and B. Roerig
Developmental Plasticity of Inhibitory Circuitry
J. Neurosci., October 11, 2006; 26(41): 10358 - 10361.
[Full Text] [PDF]
J. Hirvonen, T. G.M. van Erp, J. Huttunen, S. Aalto, K. Nagren, M. Huttunen, J. Lonnqvist, J. Kaprio, T. D. Cannon, and J. Hietala
Brain Dopamine D1 Receptors in Twins Discordant for Schizophrenia
Am J Psychiatry, October 1, 2006; 163(10): 1747 - 1753.
[Abstract] [Full Text] [PDF]
Z. Delawalla, D. M. Barch, J. L. Fisher Eastep, E. S. Thomason, M. J. Hanewinkel, P. A. Thompson, and J. G. Csernansky
Factors Mediating Cognitive Deficits and Psychopathology Among Siblings of Individuals With Schizophrenia
Schizophr Bull, July 1, 2006; 32(3): 525 - 537.
[Abstract] [Full Text] [PDF]
A. L. Malizia
The role of emission tomography in pharmacokinetic and pharmacodynamic studies in clinical psychopharmacology
J Psychopharmacol, July 1, 2006; 20(4_suppl): 100 - 107.
[Abstract] [PDF]
R. Narendran, W. G. Frankle, R. Keefe, R. Gil, D. Martinez, M. Slifstein, L. S. Kegeles, P. S. Talbot, Y. Huang, D.-R. Hwang, et al.
Altered Prefrontal Dopaminergic Function in Chronic Recreational Ketamine Users
Am J Psychiatry, December 1, 2005; 162(12): 2352 - 2359.
[Abstract] [Full Text] [PDF]
T. D. Cannon, W. Hennah, T. G. M. van Erp, P. M. Thompson, J. Lonnqvist, M. Huttunen, T. Gasperoni, A. Tuulio-Henriksson, T. Pirkola, A. W. Toga, et al.
Association of DISC1/TRAX Haplotypes With Schizophrenia, Reduced Prefrontal Gray Matter, and Impaired Short- and Long-term Memory
Arch Gen Psychiatry, November 1, 2005; 62(11): 1205 - 1213.
[Abstract] [Full Text] [PDF]
C. R. Yang and L. Chen
Targeting Prefrontal Cortical Dopamine D1 and N-Methyl-D-Aspartate Receptor Interactions in Schizophrenia Treatment
Neuroscientist, October 1, 2005; 11(5): 452 - 470.
[Abstract] [PDF]
S. B Floresco, M. A Geyer, L. H Gold, and A. A Grace
Developing Predictive Animal Models and Establishing a Preclinical Trials Network for Assessing Treatment Effects on Cognition in Schizophrenia
Schizophr Bull, October 1, 2005; 31(4): 888 - 894.
[Abstract] [Full Text] [PDF]
J. H. Krystal, E. B. Perry Jr, R. Gueorguieva, A. Belger, S. H. Madonick, A. Abi-Dargham, T. B. Cooper, L. MacDougall, W. Abi-Saab, and D. C. D'Souza
Comparative and Interactive Human Psychopharmacologic Effects of Ketamine and Amphetamine: Implications for Glutamatergic and Dopaminergic Model Psychoses and Cognitive Function
Arch Gen Psychiatry, September 1, 2005; 62(9): 985 - 994.
[Abstract] [Full Text] [PDF]
W. G. Frankle, I. Lombardo, A. S. New, M. Goodman, P. S. Talbot, Y. Huang, D.-R. Hwang, M. Slifstein, S. Curry, A. Abi-Dargham, et al.
Brain Serotonin Transporter Distribution in Subjects With Impulsive Aggressivity: A Positron Emission Study With [11C]McN 5652
Am J Psychiatry, May 1, 2005; 162(5): 915 - 923.
[Abstract] [Full Text] [PDF]
A. Bertolino, G. Caforio, G. Blasi, M. De Candia, V. Latorre, V. Petruzzella, M. Altamura, G. Nappi, S. Papa, J. H. Callicott, et al.
Interaction of COMT Val108/158 Met Genotype and Olanzapine Treatment on Prefrontal Cortical Function in Patients With Schizophrenia
Am J Psychiatry, October 1, 2004; 161(10): 1798 - 1805.
[Abstract] [Full Text] [PDF]
J. Tauscher, T. Hussain, O. Agid, N. P. L.G. Verhoeff, A. A. Wilson, S. Houle, G. Remington, R. B. Zipursky, and S. Kapur
Equivalent Occupancy of Dopamine D1 and D2 Receptors With Clozapine: Differentiation From Other Atypical Antipsychotics
Am J Psychiatry, September 1, 2004; 161(9): 1620 - 1625.
[Abstract] [Full Text] [PDF]
Y.-Y. Huang, E. Simpson, C. Kellendonk, and E. R. Kandel
Genetic evidence for the bidirectional modulation of synaptic plasticity in the prefrontal cortex by D1 receptors
PNAS, March 2, 2004; 101(9): 3236 - 3241.
[Abstract] [Full Text] [PDF]
G. Winterer, R. Coppola, T. E. Goldberg, M. F. Egan, D. W. Jones, C. E. Sanchez, and D. R. Weinberger
Prefrontal Broadband Noise, Working Memory, and Genetic Risk for Schizophrenia
Am J Psychiatry, March 1, 2004; 161(3): 490 - 500.
[Abstract] [Full Text] [PDF]
M. Amargos-Bosch, A. Bortolozzi, M. V. Puig, J. Serrats, A. Adell, P. Celada, M. Toth, G. Mengod, and F. Artigas
Co-expression and In Vivo Interaction of Serotonin1A and Serotonin2A Receptors in Pyramidal Neurons of Prefrontal Cortex
Cereb Cortex, March 1, 2004; 14(3): 281 - 299.
[Abstract] [Full Text] [PDF]
S. A. Castner and P. S. Goldman-Rakic
Enhancement of Working Memory in Aged Monkeys by a Sensitizing Regimen of Dopamine D1 Receptor Stimulation
J. Neurosci., February 11, 2004; 24(6): 1446 - 1450.
[Abstract] [Full Text] [PDF]
S. McGowan, A. D. Lawrence, T. Sales, D. Quested, and P. Grasby
Presynaptic Dopaminergic Dysfunction in Schizophrenia: A Positron Emission Tomographic [18F]Fluorodopa Study
Arch Gen Psychiatry, February 1, 2004; 61(2): 134 - 142.
[Abstract] [Full Text] [PDF]
P. M. Greenwood and R. Parasuraman
Normal Genetic Variation, Cognition, and Aging
Behav Cogn Neurosci Rev, December 1, 2003; 2(4): 278 - 306.
[Abstract] [PDF]
A. Abi-Dargham and H. Moore
Prefrontal DA Transmission at D1 Receptors and the Pathology of Schizophrenia
Neuroscientist, October 1, 2003; 9(5): 404 - 416.
[Abstract] [PDF]
S. Patel, D. J. Rademacher, and C. J. Hillard
Differential Regulation of the Endocannabinoids Anandamide and 2-Arachidonylglycerol within the Limbic Forebrain by Dopamine Receptor Activity
J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 880 - 888.
[Abstract] [Full Text] [PDF]
M. Akil, B. S. Kolachana, D. A. Rothmond, T. M. Hyde, D. R. Weinberger, and J. E. Kleinman
Catechol-O-Methyltransferase Genotype and Dopamine Regulation in the Human Brain
J. Neurosci., March 15, 2003; 23(6): 2008 - 2013.
[Abstract] [Full Text] [PDF]
P. O. Koh, C. Bergson, A. S. Undie, P. S. Goldman-Rakic, and M. S. Lidow
Up-regulation of the D1 Dopamine Receptor-Interacting Protein, Calcyon, in Patients With Schizophrenia
Arch Gen Psychiatry, March 1, 2003; 60(3): 311 - 319.
[Abstract] [Full Text] [PDF]
P. O. Koh, C. Bergson, A. S. Undie, P. S. Goldman-Rakic, and M. S. Lidow
Up-regulation of the D1 Dopamine Receptor-Interacting Protein, Calcyon, in Patients With Schizophrenia
Arch Gen Psychiatry, March 1, 2003; 60(3): 311 - 319.
[Abstract] [Full Text]
K. Tumova, R. M. Iwasiow, and M. Tiberi
Insight into the Mechanism of Dopamine D1-like Receptor Activation. EVIDENCE FOR A MOLECULAR INTERPLAY BETWEEN THE THIRD EXTRACELLULAR LOOP AND THE CYTOPLASMIC TAIL
J. Biol. Chem., February 28, 2003; 278(10): 8146 - 8153.
[Abstract] [Full Text] [PDF]
N. Gorelova, J. K. Seamans, and C. R. Yang
Mechanisms of Dopamine Activation of Fast-Spiking Interneurons That Exert Inhibition in Rat Prefrontal Cortex
J Neurophysiol, December 1, 2002; 88(6): 3150 - 3166.
[Abstract] [Full Text] [PDF]
K. A. Albert, H. C. Hemmings Jr, A. I. B. Adamo, S. G. Potkin, S. Akbarian, C. A. Sandman, C. W. Cotman, W. E. Bunney Jr, and P. Greengard
Evidence for Decreased DARPP-32 in the Prefrontal Cortex of Patients With Schizophrenia
Arch Gen Psychiatry, August 1, 2002; 59(8): 705 - 712.
[Abstract] [Full Text] [PDF]
|
|
|
|
 |
|